Literature DB >> 20953917

Methamphetamine causes persistent immune dysregulation: a cross-species, translational report.

Jennifer M Loftis1, Dongseok Choi, William Hoffman, Marilyn S Huckans.   

Abstract

Methamphetamine (MA) dependence causes serious cognitive impairments that can persist during abstinence and negatively affect recovery outcomes. Evidence suggests that immune factors, such as cytokines, chemokines, and cellular adhesion molecules, contribute to MA-induced immune dysfunction, neuronal injury, and persistent cognitive impairments, yet the role of MA-induced brain inflammation remains unclear. To address this question, we used a cross-species, translational approach. Thirty-two male C57BL/6J mice were administered MA (1 mg/kg) or saline subcutaneously for seven consecutive days. Mice were euthanized at 72 h or 3 weeks after the last drug dose, and blood and brain samples were collected. In addition, 20 adults in remission from MA dependence and 20 non-dependent controls completed neuropsychological assessments and a blood draw. Multiplex assays were used to measure cytokine, chemokine, and intercellular adhesion molecule (ICAM-1) expression in mouse and human samples. A number of significant MA-induced changes in neuroimmune factors were observed. Of particular interest were the chemokine monocyte chemoattractant protein 1 (MCP-1) and the cellular adhesion molecule ICAM-1, which were similarly increased in the plasma of MA exposed mice as well as humans. In human participants, MA-induced changes in the cytokine and chemokine milieu were accompanied by increased cognitive impairments. Mice showing MA-induced changes in peripheral immune molecule expression also had significant brain-region specific changes in pro-inflammatory cytokines, chemokines, and ICAM-1. This cross-species, translational study suggests that chronic CNS immune dysregulation may in part contribute to the longlasting neuropsychiatric consequences of MA dependence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20953917      PMCID: PMC3081419          DOI: 10.1007/s12640-010-9223-x

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  64 in total

Review 1.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

2.  Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters.

Authors:  H M Haughey; J M Brown; D G Wilkins; G R Hanson; A E Fleckenstein
Journal:  Brain Res       Date:  2000-04-28       Impact factor: 3.252

3.  Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; Y S Ding; M Sedler; J Logan; D Franceschi; J Gatley; R Hitzemann; A Gifford; C Wong; N Pappas
Journal:  Am J Psychiatry       Date:  2001-12       Impact factor: 18.112

4.  Cognitive efficiency is associated with endogenous cytokine levels in patients with chronic hepatitis C.

Authors:  Robin C Hilsabeck; Gregory M Anstead; Amy L Webb; Anastasio Hoyumpa; Paul Ingmundson; Steve Holliday; Qiong Zhang; Angela M Casas; Marci Jovel; Stephen L Stern
Journal:  J Neuroimmunol       Date:  2010-02-24       Impact factor: 3.478

5.  Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines.

Authors:  Jiraporn Tocharus; Chakkrapong Khonthun; Sukumal Chongthammakun; Piyarat Govitrapong
Journal:  J Pineal Res       Date:  2010-03-31       Impact factor: 13.007

6.  Regional heterogeneity and diversity in cytokine and chemokine production by astroglia: differential responses to HIV-1 Tat, gp120, and morphine revealed by multiplex analysis.

Authors:  Sylvia Fitting; Shiping Zou; Wen Chen; Phu Vo; Kurt F Hauser; Pamela E Knapp
Journal:  J Proteome Res       Date:  2010-04-05       Impact factor: 4.466

7.  Methamphetamine reduces LTP and increases baseline synaptic transmission in the CA1 region of mouse hippocampus.

Authors:  Jarod Swant; Sanika Chirwa; Gregg Stanwood; Habibeh Khoshbouei
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

8.  Global and local morphometric differences in recently abstinent methamphetamine-dependent individuals.

Authors:  Daniel L Schwartz; Alex D Mitchell; David L Lahna; Hannah S Luber; Marilyn S Huckans; Suzanne H Mitchell; William F Hoffman
Journal:  Neuroimage       Date:  2010-01-22       Impact factor: 6.556

9.  Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice.

Authors:  Qianli Yu; Dongqin Zhang; Michael Walston; Jin Zhang; Yingyin Liu; Ronald R Watson
Journal:  Int Immunopharmacol       Date:  2002-06       Impact factor: 4.932

10.  Interaction of atherosclerosis and inflammation in elderly subjects with poor cognitive function.

Authors:  E van Exel; A J M de Craen; E J Remarque; J Gussekloo; P Houx; A Bootsma-van der Wiel; M Frölich; P W Macfarlane; G J Blauw; R G J Westendorp
Journal:  Neurology       Date:  2003-12-23       Impact factor: 9.910

View more
  68 in total

Review 1.  Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection.

Authors:  Kenneth H Clark; Clayton A Wiley; Charles W Bradberry
Journal:  Neurotox Res       Date:  2012-06-20       Impact factor: 3.911

2.  The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice.

Authors:  Sarah E Snider; Sarah A Vunck; Edwin J C G van den Oord; Daniel E Adkins; Joseph L McClay; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2012-01-28       Impact factor: 4.432

Review 3.  Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways.

Authors:  Irina N Krasnova; Zuzana Justinova; Jean Lud Cadet
Journal:  Psychopharmacology (Berl)       Date:  2016-02-12       Impact factor: 4.530

4.  Unique genetic factors influence sensitivity to the rewarding and aversive effects of methamphetamine versus cocaine.

Authors:  Noah R Gubner; Cheryl Reed; Carrie S McKinnon; Tamara J Phillips
Journal:  Behav Brain Res       Date:  2013-08-28       Impact factor: 3.332

5.  Neuronal development genes are key elements mediating the reinforcing effects of methamphetamine, amphetamine, and methylphenidate.

Authors:  Ike Dela Peña; Se Jin Jeon; Eunyoung Lee; Jong Hoon Ryu; Chan Young Shin; Minsoo Noh; Jae Hoon Cheong
Journal:  Psychopharmacology (Berl)       Date:  2013-06-20       Impact factor: 4.530

6.  Parallel Effects of Methamphetamine on Anxiety and CCL3 in Humans and a Genetic Mouse Model of High Methamphetamine Intake.

Authors:  Marilyn Huckans; Clare J Wilhelm; Tamara J Phillips; Elaine T Huang; Rebekah Hudson; Jennifer M Loftis
Journal:  Neuropsychobiology       Date:  2018-01-18       Impact factor: 2.328

7.  Decreased Expression of Plasma MicroRNA in Patients with Methamphetamine (MA) Use Disorder.

Authors:  Yan Zhao; Kai Zhang; Haifeng Jiang; Jiang Du; Zong Na; Wei Hao; Shunying Yu; Min Zhao
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-23       Impact factor: 4.147

8.  Reductions in frontocortical cytokine levels are associated with long-lasting alterations in reward valuation after methamphetamine.

Authors:  Alexandra Stolyarova; Andrew B Thompson; Ruth M Barrientos; Alicia Izquierdo
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

Review 9.  Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review.

Authors:  Eric A Woodcock; Ansel T Hillmer; Graeme F Mason; Kelly P Cosgrove
Journal:  Mol Neuropsychiatry       Date:  2019-05-09

10.  Chemokines and 'bath salts': CXCR4 receptor antagonist reduces rewarding and locomotor-stimulant effects of the designer cathinone MDPV in rats.

Authors:  Chicora F Oliver; Steven J Simmons; Sunil U Nayak; Garry R Smith; Allen B Reitz; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.